IP Library Granted Patent US 8,888,840
Granted Patent B2
US 8,888,840 · App. 13/863,632 · Granted Nov 18, 2014

Drug eluting medical implant

Inventors: Maria Palasis (Wellesley, MA); Changcheng You (Northbridge, MA); Daniel Concagh (Medfield, MA); Lee Core (Needham, MA); Kirchel Ho (Groton, MA); Upma Sharma (Somerville, MA); Gregory T. Zugates (Chelmsford, MA)
Assignee: Boston Scientific Scimed, Inc.
A61F2/06A61L29/085A61F2/90A61L31/10A61F2250/0067A61F2300/416A61L31/16A61L2420/02A61L2420/08A61L29/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,888,840
App. No.
13/863,632
Granted
Nov 18, 2014
Kind
B2
Abstract

Disclosed are self-expanding medical implants for placement within a lumen of a patient. The implants comprise a woven or non-woven structure having a substantially tubular configuration, and are designed to be low-profile such that they are deliverable with a small diameter catheter. The implants have a high recoverability and desired mechanical properties.

Claims (22)

1. A medical implant comprising:

a tubular structure comprising a first polymeric material;

a first conformal coating comprising poly(lactic acid-co-caprolactone), said first conformal coating at least partially coating said tubular structure and increasing the mass of said tubular structure by at least about 20 percent;

a second conformal coating at least partially coating said first conformal coating and comprising a second polymeric material and paclitaxel, said second conformal coating comprising between 0.3 weight percent and 5 weight percent of paclitaxel.

2. The medical implant of claim 1 , wherein said poly(lactic acid-co-caprolactone) comprises about 50 weight percent of lactic acid and about 50 weight percent of caprolactone.

3. The medical implant of claim 2 , wherein said poly(lactic acid-co-caprolactone) is prepared by a process that comprises the step of crosslinking said poly(lactic acid-co-caprolactone) with diisocyanate.

4. The medical implant of claim 3 , wherein said diisocyanate is hexamethylene diisocyanate.

5. The medical implant of claim 1 , wherein said first polymeric material comprises poly(lactic acid co-glycolic acid).

6. The medical implant of claim 1 , wherein said second conformal coating has a thickness up to 8 microns.

7. The medical implant of claim 1 , wherein the medical implant comprises between 2.5 micrograms and 20 micrograms of paclitaxel per 10 millimeters of length of the tubular structure.

8. The medical implant of claim 7 , wherein the medical implant comprises between 5 micrograms and 13 micrograms of paclitaxel per 10 millimeters of length of the tubular structure.

9. A medical implant comprising:

a tubular structure comprising a first polymeric material;

a first conformal coating comprising poly(lactic acid-co-caprolactone), said first conformal coating at least partially coating said tubular structure and increasing the mass of said tubular structure by at least about 20 percent;

a second conformal coating at least partially coating said first conformal coating and comprising a second polymeric material and paclitaxel, said second conformal coating comprising between 2.5 micrograms and 20 micrograms of paclitaxel per 10 millimeters of length of the tubular structure.

10. The medical implant of claim 9 , wherein said second conformal coating comprises between 5 micrograms and 13 micrograms of paclitaxel per 10 millimeters of length of the tubular structure.

11. The medical implant of claim 9 , wherein said poly(lactic acid-co-caprolactone) comprises about 50 weight percent of lactic acid and about 50 weight percent of caprolactone.

12. The medical implant of claim 9 , wherein said poly(lactic acid-co-caprolactone) is prepared by a process that comprises the step of crosslinking said poly(lactic acid-co-caprolactone) with diisocyanate.

13. The medical implant of claim 12 , wherein said diisocyanate is hexamethylene diisocyanate.

14. The medical implant of claim 9 wherein said first polymeric material comprises poly(lactic acid co-glycolic acid).

15. The medical implant of claim 9 , wherein said second conformal coating has a thickness up to 8 microns.

16. The medical implant of claim 9 , wherein the second conformal coating comprises between 0.3 weight percent and 5 weight percent of paclitaxel.

Assignments (2)
CHANGE OF NAME Recorded Jan 17, 2020
From: 480 BIOMEDICAL, INC.
To: LYRA THERAPEUTICS, INC.
Reel/Frame 051637/0116 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2013
From: PALASIS, MARIA; YOU, CHANGCHENG; CONCAGH, DANNY; CORE, LEE; HO, KICHERL; SHARMA, UPMA; ZUGATES, GREG
To: 480 BIOMEDICAL, INC.
Reel/Frame 030509/0514 →
Continuity (11)
Continuation In Part 13766294 · Feb 13, 2013
Continuation In Part 13370025 · Feb 9, 2012
Continuation In Part 13253720 · Oct 5, 2011
Continuation In Part 13183104 · Jul 14, 2011
Continuation In Part 13032281 · Feb 22, 2011
Continuation In Part 12783261 · May 19, 2010
Provisional Application 61624607 · Apr 16, 2012
Provisional Application 61179834 · May 20, 2009
Provisional Application 61227308 · Jul 21, 2009
Provisional Application 61251984 · Oct 15, 2009
Related Publication 20130317600A1 · Nov 28, 2013